Edition:
United States

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

68.60CHF
9:56am EDT
Change (% chg)

CHF0.00 (+0.00%)
Prev Close
CHF68.60
Open
CHF68.30
Day's High
CHF69.40
Day's Low
CHF68.05
Volume
16,006
Avg. Vol
60,401
52-wk High
CHF123.10
52-wk Low
CHF58.80

Summary

Name Age Since Current Position

Domenico Scala

51 2016 Chairman of the Board

Ronald Scott

60 2013 Chief Executive Officer, Member of the Management Committee

Donato Spota

2013 Member of the Management Board, Chief Financial Officer

Heidi McDaid

2013 Head of Global Human Resources

Ingrid Heinze-Krauss

2006 Member of the Management Committee, Chief Technology Officer

Laurenz Kellenberger

2009 Member of the Management Committee, Chief Scientific Officer

David Veitch

49 2014 Chief Commercial Officer, Member of the Management Committee

Achim Kaufhold

2010 Member of the Management Committee, Chief Medical Officer

Hans-Beat Guertler

69 2013 Member of the Board of Directors

Daniel Lew

67 2003 Member of the Board of Directors

Martin Nicklasson

61 2016 Director

Thomas Rinderknecht

61 2011 Member of the Board of Directors

Steven Skolsky

59 2011 Member of the Board of Directors

Thomas Werner

60 2011 Member of the Board of Directors

Barbara Zink

Head - Corporate Development

Biographies

Name Description

Domenico Scala

Mr. Domenico Scala has been Chairman of the Board of the Company. He was Vice Chairman of the Board of Directors at Basilea Pharmaceutica Ltd. Previously, he was Member of the Board of Directors at the company as of April 6, 2011. From 2007 to 2011 he was President and Chief Executive Officer of Nobel Biocare Holding AG and from 2003 to 2007 Chief Financial Officer of Syngenta International AG. From 1995 to 2003 he served in various senior leadership positions at Roche Holding AG and prior to that as Finance Director with Panalpina Italy Spa and Senior Auditor with Nestlé SA. Since May 2012 he is Chairman of the Audit and Compliance Committee of FIFA (Football Association). Since May 2014 he is Board member at BAK Basel Economics AG. He also acts as Senior Advisor to Private Equity and M&A firms. In 2004 he was one of a selected few executives to be named "Young Global Leader" by the World Economic Forum (WEF). Mr. Scala graduated from the University of Basel with a degree in economics. He holds executive development degrees from INSEAD and London Business School. He is also a member of the Board of Overseers of the Tufts University, Boston, USA.

Ronald Scott

Mr. Ronald Scott has been Chief Executive Officer, Member of the Management Committee of Basilea Pharmaceutica AG since January 1, 2013. He was Basilea’s COO from January 2012 through December 2012, and served as Basilea’s CFO from the Company’s founding in 2000 through January 2012 as well as ad interim CFO from February 7, 2013 until November 4, 2013. Prior to joining the Company, he worked for nine years at Roche in management positions in Pharmaceutical Finance, Licensing and the Roche Corporate Finance Mergers and Acquisitions group. His assignments included managing Roche's call, primary and secondary offerings on Genetech, Roche's biotechnology investment portfolio, acquisitions and divestitures. Prior to joining Roche, Mr. Scott worked for Prudential Investment Corporation as Director in Finance and International Business Development Units, managing divestitures and joint venture transactions.

Donato Spota

Mr. Donato Spota serves as Member of the Management Board, Chief Financial Officer of Basilea Pharmaceutica AG since 2013. He has over 16 years of experience in the pharma industry, including finance, strategic financial planning and analysis, budgeting, information technology as well as audit and risk management. Prior to his appointment to CFO, he was Basilea’s Global Head of Finance and Services, assuming responsibilities for Finance, Information Technology and General Services. Before joining Basilea in 2002, Mr. Spota worked for F. Hoffmann - La Roche Basel in the area of pharma global informatics financial planning and controlling. He holds a master degree in business administration of the University of Applied Sciences Nuertingen, Germany. He also holds a diploma in information technology.

Heidi McDaid

Ms. Heidi McDaid has served as Head of Global Human Resources of Basilea Pharmaceutica AG since January 1, 2013. She has both business management and human resources qualifications. She has held various positions in finance and administration at Bank und Finanz-Institut AG, Bank CIAL (Schweiz) AG and Lubapharm AG. Before joining Basilea in 2002 as Head of Human Resources, she worked for Mepha AG in the domain of Finance and Human Resources. For many years she served as President of the Board of Trustees of the Basilea Pension Fund and is now member of the Board of Trustees of the collective foundation.

Ingrid Heinze-Krauss

Dr. Ingrid Heinze-Krauss Ph.D., has been Member of the Management Committee and Chief Technology Officer at Basilea Pharmaceutica AG since 2006. She holds a Doctorate in Philosophy degree in Organic Chemistry from Universitaet Freiburg and was Fellow at University of Massachusetts. She joined the Company in 2001 and built up the supply chain management group. Prior to joining the Company, she held a series of managerial positions in Pharma Research at Roche, including Area Head Medicinal Chemistry in Antibacterial Research and Research and Development project management.

Laurenz Kellenberger

Dr. Laurenz Kellenberger, Ph.D., has been Member of the Management Committee and Chief Scientific Officer of Basilea Pharmaceutica AG since January 27, 2009. He holds a Doctorate in Philosophy degree in Organic Chemistry from Swiss Federal Institute of Technology (ETH Zuerich). He continued his scientific research at University of Cambridge and at Hoffmann-La Roche, where he held different positions in preclinical research and chemical technologies before joining the Company in 2000. He is author of a number of scientific publications. At the Company, he held various roles of increasing responsibility and served as Head of Chemistry and Member of the Research Management Team with responsibilities for key projects from lead finding and optimization through to preclinical development. He is a member of the Board of the Medicinal Chemistry & Chemical Biology division of the Swiss Chemical Society.

David Veitch

Mr. David Veitch has been Chief Commercial Officer, Member of the Management Committee of Basilea Pharmaceutica Ltd since September 1, 2014. He is a British citizen and has over 25 years of international commercial experience in the pharmaceutical industry, leading cross-functional organizations at the country and European level, and was responsible for the launch of numerous brands across many therapeutic areas. Most recently he was President European Operations at Savient Pharmaceuticals. Prior to Savient, from 1996 to 2011, Mr. Veitch held various positions with increasing responsibilities at Bristol-Myers Squibb UK and Europe. Mr. Veitch's last position at Bristol-Myers Squibb was Senior Vice President Europe, Middle-East and Asia, Marketing and Brand Commercialization, leading the commercial organization for the region with a focus on specialty care brands. He started his pharma career in 1987 at SmithKline Beecham Pharmaceuticals, UK. Mr. Veitch holds a Bachelor of Science degree in biology from the University of Bristol, UK.

Achim Kaufhold

Prof. Achim Kaufhold, M.D., has been Member of the Management Committee and Chief Medical Officer of Basilea Pharmaceutica AG since February 1, 2010. He holds a medical degree from Universitaet zu Koeln. He worked in the fields of pediatrics, basic and applied medical microbiology, laboratory medicine and infectious diseases in Germany and the United States. He is Professor of Medical Microbiology and Infectious Diseases and Member of the Faculty of Medicine of the University of Aachen. Prof. Kaufhold has spent more than 17 years in senior management positions in the biotechnology and pharmaceutical industry, mainly in leadership roles in research, product and business development, and general management. Prior to joining the Company, he was President & Chief Executive Officer of Affitech A/S, previously Pharmexa A/S. His previous senior management roles included Chief Medical Officer & Vice President of Development, Member of the Executive Committee at Chiron, now part of the Novartis group. He was also Chief Medical Officer, Head of Research, Product & Business Development, Member of the Executive Committee at Berna Biotech, now a Crucell company. He was also Director Clinical Development & Head of the Pediatric Vaccines Development Unit at GlaxoSmithKline Biologicals with global responsibility for the development of that company's pediatric vaccine portfolio.

Hans-Beat Guertler

Mr. Hans-Beat Guertler has been Member of the Board of Directors of Basilea Pharmaceutica AG since April 9, 2013. Previously, he served as Vice Chairman of the Board of Directors at the company since April 6, 2011. Prior to that, he served as Member of the Board of Directors of the Company from April 29, 2009. He holds a Commercial Diploma. He also serves as Management Partner for entrepreneurial investments of Varuma AG and is Member and President of the Boards of Directors of several Swiss-based companies, most of them start-ups and Small and Medium companies (SMEs), primarily in the pharmacy and biotechnology sector. Prior to joining Varuma AG, Mr. Guertler held position of Global Chief Executive Officer of Novartis Animal Health, where he was responsible for the worldwide business, including research, development, manufacturing and marketing of animal pharmaceuticals for pets and farm animals. Previously, he held various management positions at Ciba-Geigy Ltd, including business responsibilities in Eastern Europe, the Northern Hemisphere and the global pest-control business. He was also Chief Executive Officer of Ciba-Geigy Ltd's Seed business company, Mahissa. He has been Member of the Compensation Committee and Audit Committee at the Company since April 29, 2009.

Daniel Lew

Prof. Daniel Lew M.D., has been Member of the Board of Directors at Basilea Pharmaceutica AG since 2003. He is Professor of Medicine at University of Geneva Medical School and Chief of the Service of Infectious Diseases, Department of Internal Medicine at the Geneva University Hospitals. He obtained his Doctorate of Medicine degree from Universite de Geneve in 1976. He specialized in infectious diseases both in Geneva and then subsequently at Harvard Medical School and Massachusetts General Hospital. He is recipient of a number of scientific awards and grants for his research work. He lectures and acts both as Reviewer and Editor for several scientific journals, and is Author of a number of publications on neutrohil function, bacterial pathogenesis and drug resistance. Prof. Lew is President of the International Society for Infectious Diseases (ISID). He is Member of the Audit Committee at the Company and was Member of the Compensation Committee.

Martin Nicklasson

Dr. Martin Nicklasson, Ph.D., is Director of the Company. He was Chairman of the Board of Directors of Basilea Pharmaceutica Ltd. He is a certified pharmacist and holds a PhD in pharmaceutical technology from the University of Uppsala, Sweden. He is Associate Professor at the Department of Pharmaceutics, University of Uppsala. Dr. Nicklasson held a number of leadership positions in commercial operations and drug development within Astra and Kabi Pharmacia before joining AstraZeneca Plc. From 1999 to 2007 he held various Executive Vice President positions at AstraZeneca Plc., and acted as a member of the Executive Committee. From 2007 to 2010, he was the President and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB, one of Europe’s largest specialties Pharma companies focusing on rare diseases. He is currently a senior partner at Nicklasson Life Science AB, an independent consultancy and advisory company to the pharmaceutical and biotechnology sector. Dr. Nicklasson is member of the board of Biocrine AB (Sweden), PledPharma AB (Sweden), Premier Research Group Ltd. (UK), Pozen Inc. (USA), Oasmia AB (Sweden) and chairman of the board of directors of Farma Holding AS (Norway) and Orexo AB (Sweden). He is member of the Royal Swedish Academy of Engineering Sciences, the Royal Bachelors’ Club (Sweden), the Pharmaceutical Faculty Council of the University of Uppsala, and the Swedish Academy of Pharmaceutical Sciences.

Thomas Rinderknecht

Dr. Thomas M. Rinderknecht M.D., has been appointed as Member of the Board of Directors at Basilea Pharmaceutica AG as of April 6, 2011. He is an attorney-at-law and senior partner at Badertscher Rechtsanwaelte AG, Zurich and Zug. He has served on the Boards of Directors of several biotech, pharma and medtech companies including Speedel AG, Basel, Glycart Biotechnology AG, Schlieren, and Ganymed Pharmaceuticals AG, Mainz, Germany. He serves as Chairman of Canyon Pharmaceuticals AG, Zug, and Vice-Chairman of APR Applied Pharma Research SA, Balerna. Dr. Rinderknecht holds a Ph.D. in law from the University of Zurich and is admitted to the Bar in Zurich, Switzerland.

Steven Skolsky

Mr. Steven D. Skolsky has been appointed Member of the Board of Directors at Basilea Pharmaceutica AG as of April 6, 2011. Prior to that, he served as Vice Chairman of the Board of Directors of the Company since April 29, 2009. He has served as Member of the Board of Directors from March 19, 2008 until April 29, 2009. He holds a Bachelor of Arts degree in Biology from University of North Carolina at Chapel Hill. He has many years experience in general management in pharmaceutical industry with emphasis on product strategy, commercialization and product development. He also serves as President and Chief Executive Officer of Sequoia Pharmaceuticals. Prior to appointment at Sequoia Pharmaceuticals, he held position of Chief Executive Officer at Trimeris Inc. Previously, he served at GlaxoSmithKline in a range of senior leadership roles, including Senior Vice President, Global Product Strategy and Clinical Development, and Managing Director of that company's operations in Australia and New Zealand. He is Member of the Compensation Committee at the Company.

Thomas Werner

Dr. Thomas Werner has been Member of the Board of Directors at Basilea Pharmacetica AG as of November 29, 2011. He has over 28 years of experience in the pharmaceutical industry, most recently as Senior Vice President of GlaxoSmithKline where he was Managing Director for Germany and also coordinated the European oncology business. Prior to that, he was responsible for Glaxo Wellcome Germany and Central Europe, Bristol-Myers Squibb Germany and Convatec Germany/Central Europe. Dr. Werner sits on the boards of SkyePharma plc, Medigene AG, 4SC AG and SuppreMol GmbH as well as on the board of trustees of the Paul Ehrlich Foundation. He holds a degree in chemistry from the University of Goettingen.

Barbara Zink